ERBB2 and breast carcinoma: Clinical validation of this approach is emerging, with combinations such as trastuzumab deruxtecan (T-DXd) plus pembrolizumab demonstrating improved responses in refractory HER2-low breast cancer and mismatch repair-deficient tumors [11, 12].